Evaluation of tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication

International Braz J Urol

Volumn 38, Issue 1, 2012, Pages 33-39

  Madani, Ali Hamidi ^a   Afsharimoghaddam, Amin ^a   Roushani, Ali ^a   Farzan, Alireza ^a   Asadollahzade, Ahmad ^a   Shakiba, Maryam ^a  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Benign prostatic hyperplasia; Erectile dysfunction; Prostate; Quality of life; Tadalafil

Indexed keywords

CARBOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; TADALAFIL;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; MIDDLE AGED; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; CARBOLINES; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PLACEBOS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84865355229     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382012000100005     Document Type: Article

References (28)

1. Claus G. Rohrborn, John D. Mc Connell: Benign prostatic hyperplasia: Etiology, Pathophysiology, Epidemiology and Natural History In: Kavoussi, Novick, Patrin, Peters.Campbell-Walsh Urology. V.3. qth ed. SAUNDERS. 2007: pp. 2727-65.
2. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB: Sexual function in men older than 50 years of age: results from the health professionals followup study. Ann Intern Med. 2003; 139: 161-8.
3. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. EurUrol. 2006; 49: 651-8.
4. Schiff JD, Mulhall JP: The link between LUTS and ED: clinical and basic science evidence. J Androl. 2004; 25: 470-8.
5. Joseph C, Presti Jr.: Neoplasms of the Prostate Gand. In:Tanagho EA, McAnich JW, (ed.), Smith's General Urology.6th. New York, McGraw-Hill, 2004: p. 371-2.
6. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P: Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 2006; 98: 1259-63.
7. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, et al.: Characterization and functional role of androgendependent PDE5 activity in the bladder. Endocrinology. 2007; 148: 1019-29.
8. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB,Hanbury DC: Sildenafil influences lower urinary tract symptoms.BJU Int. 2002; 90: 836-9.
9. Giuliano F: Phosphodiesterase type 5 inhibitors improve male lower urinary tract symptoms. Eur Urol. 2008; 53:1121-3; discussion 1123-4.
10. Moreira ED Jr, Lbo CF, Diament A, Nicolosi A, Glasser DB:Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil.Urology. 2003; 61: 431-6.
11. Bosch JL, Kranse R, van Mastrigt R, SchrÖder FH: Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol. 1995; 153: 689-93.
12. Andersson KE: Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol. 2002; 19: 390-6.
13. Kester RR, Mooppan UM, Gousse AE, Alver JE, Gintautas J, Gulmi FA, et al.: Pharmacological characterization of isolated human prostate. J Urol. 2003; 170: 1032-8. Erratum in: J Urol. 2003; 170: 2394.
14. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, et al.: Characterization and localization of nitric oxide synthase in the human prostate. Urology. 1995; 45:435-9.
15. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H: Effects of nitric oxide on human and canine prostates. Urology.1995; 45: 440-6.
16. Uckert S, Küthe A, Jonas U, Stief CG: Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol. 2001; 166:2484-90.
17. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB: Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol. 2003; 170: 659-63.
18. Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, et al.: Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005; 96: 1073-8.
19. Pinggera GM, Mitterberger M, Pallwein L, Schuster A, Herwig R, Frauscher F, et al.: Alpha-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int. 2008; 101: 319-24.
20. Andersson KE, Uckert S, Stief C, Hedlund P: Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.Neurourol Urodyn. 2007; 26(6 Suppl): 928-33.
21. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM,Wachs B, Young JM, et al.: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.J Urol. 2007; 177: 1401-7.
22. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ,van den Ende G: Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol.2007; 177: 1071-7.
23. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E: A randomised,placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008; 53: 1236-44.
24. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L: Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology. 2010;75: 1452-8.
25. Kim TB, Kim KH, Yoon SJ: Open-label, Intermittent Dose,Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects. Int Neurourol J. 2010; 14: 7-12.
26. Mirone V, Costa P, Damber JE, Holmes S, Moncada I, Van Ahlen H, et al.: An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction:SURE study in 14 European countries. Eur Urol.2005; 47: 846-54; discussion 854.
27. McMahon C: Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005; 2: 415-25; discussion 425-7.
28. Bella AJ, Deyoung LX, Al-Numi M, Brock GB: Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol. 2007; 52:990-1005.